Article Dans Une Revue Vaccine Année : 2009

A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy

Nidia Alvarez-Rueda
Maha Zohra Ladjemi
Stéphanie Corgnac
Martine Pugnière
Françoise Roquet
  • Fonction : Auteur
Caroline Bascoul-Mollevid
  • Fonction : Auteur
Daniel Baty
  • Fonction : Auteur
André Pèlegrin
Isabelle Navarro-Teulon
  • Fonction : Auteur

Résumé

HER2 over-expression in breast cancer correlates with reduced survival. Anti-idiotypic antibodies (Abs) that closely mimic HER2 could play a crucial role in the development of effective therapeutic vaccines. Here, we show that an anti-idiotypic single domain antibody (sdAb) 1HE isolated from a library generated from a Trastuzumab F(ab′)2-immunized llama, closely mimics HER2. SdAb 1HE shows high affinity for Trastuzumab F(ab′)2, selectively inhibits HER2 binding to Trastuzumab F(ab′)2, and sera from sdAb 1HE-immunized BALB/c mice contain anti-HER2 antibodies that inhibit viability of HER2-positive cells. These results indicate that sdAb 1HE could be used as an anti-idiotype-based vaccine to boost immunity in patients bearing HER2-positive tumours.

Domaines

Fichier non déposé

Dates et versions

hal-00414283 , version 1 (08-09-2009)

Identifiants

  • HAL Id : hal-00414283 , version 1

Citer

Nidia Alvarez-Rueda, Maha Zohra Ladjemi, Ghislaine Béhar, Stéphanie Corgnac, Martine Pugnière, et al.. A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine, 2009, 27 (35), pp.4826-4833. ⟨hal-00414283⟩
208 Consultations
0 Téléchargements

Partager

  • More